CClinicalTrials.gg
Sign In
CompletedNCT03271476PSYCANCERUpdated Jun 25, 2026

EMDR Psychotherapy to Treat Anxious-depressive Symptoms in Breast Cancer Patient

An interventional study of EMDR psychotherapy in Breast Cancer, Eye Movement Desensitization and Processing and Psychoterapy, sponsored by Centre Hospitalier Régional Metz-Thionville. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The study will consist in an adjustment/adaptation of the "standard EMDR protocol" for cancer disease, and most particulary for women who present a breast cancer and during adjuvant therapy. It will also test the faisability of the research, with a view to adjust the calendar and the ressources to put at disposal for a randomized control trial that follow. This study will also allow to test the need and acceptibility of this new psychotherapy for the patient, and to identify facilitators and obstacles : participation/rejection ratio, inclusion rythm, adhesion of the medical staff about the project

02

Conditions studied

  • Breast Cancer
  • Eye Movement Desensitization and Processing
  • Psychoterapy

Browse trials for

Keywords

  • Breast Cancer
  • EMDR
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Being a woman aged of 18 years or more
  • Having a primary invasive breast cancer
  • Having undergo a mastectomy for a primary invasive breast cancer
  • Being able to complete the questionnaires
  • Being informed of the study and having signed the informed consent
  • Being affiliated to a welfare system

Exclusion criteria

Exclusion Criteria:

  • having contraindications to recieve EMDR psychotherapy (neurologic disorders, dissociatif states, oculomotor issues)
  • Having started adjuvant treatments following surgery
  • Having metastatic breast cancer
  • Presenting physical polypathologies
  • Having psychiatric antecedents (included anxiety and depressif disorders - assessed with M.I.N.I. (Sheehan and al., 1997)).
  • Having drug or alcohol addiction
  • Being placed under the safeguard of justice, guardianship or trusteeship
  • Being pregnant or breast-feeding
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arms

    Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)

    Behavioral: EMDR psychotherapy

Interventions

  • BehavioralEMDR psychotherapy

    Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)

05

What researchers measure

Primary outcomes

  1. patients involvement

    acceptability of the new psychotherapy

    Time frame: week 12

Secondary outcomes

  1. adequacy of the intervention with the field

    adaptability of the EMDR protocol

    Time frame: Week 12

  2. EMDR psychotherapy efficacy during the study, we will survey our population several times with differents questionnaires

    ratio of patients which wants to participate and effectively participate

    Time frame: Week 12

06

Study locations

1 site
  • CHR Metz-Thionville
    Metz, 57085, France
07

References and documents

Publications

  • Tarquinio, C. , Machado, J. , Longo, R. , Siles, J. , Bruno, J. , Gendarme, S. , Ziegler, A. , Mellouki, N. , Eby, E. and Rotonda, C. (2022) The Treatment of Anxious-Depressive Disorders among Breast Cancer Patients Integrating the EMDR Psychotherapy: From Pilot Study Results to the Development of a Randomized Trial. Psychology, 13, 313-327. doi: 10.4236/psych.2022.133019.

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03271476
Lead sponsor
Centre Hospitalier Régional Metz-Thionville
Collaborators
University of Lorraine
Responsible party
Sponsor
First posted
Sep 5, 2017
Start date
Sep 1, 2017
Primary completion
Jul 25, 2018
Completion
Jul 25, 2018
Last update
Jun 25, 2026

Study contacts

Rafaele Longo, Dr
principal investigator · CHR Metz-Thionville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breast Neoplasms→

Other studies from this sponsor

Centre Hospitalier Régional Metz-Thionville

Start the discussion